Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ICVB-1042 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors IconOVir Bio

    • Most Recent Events

    • 11 Jul 2023 According to an IconOVir Bio media release, first patient has been dosed in this study. The company plans reporting initial safety data later this year, with potential biological proof-of-concept in the first half of 2024.
    • 06 Jun 2023 Status changed from planning to recruiting.
    • 05 Oct 2022 According to an IconOVir Bio media release, the company plans to advance into this Phase 1 study evaluating IV-administered ICVB-1042 in solid tumors in the first half of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top